Newron to Highlight Phase III Evenamide Data at 2026 Schizophrenia Congress

Newron Pharmaceuticals SpA ( (CH:NWRN) ) has provided an update.

Newron Pharmaceuticals will showcase new data on its lead drug candidate Evenamide at the 2026 Schizophrenia International Research Society congress in Florence, highlighting glutamatergic modulation as a potential approach for treatment-resistant schizophrenia. The company will lead a workshop and present three posters spanning preclinical findings, Phase III ENIGMA-TRS program updates and evidence of benefits on social functioning and life engagement in patients who respond poorly to existing antipsychotics.

The presentations underscore the strategic importance of Evenamide as a first-in-class add-on therapy targeting glutamate dysfunction, a key mechanism believed to underlie resistance to current dopamine-focused antipsychotics. Positive clinical data and the progress of the ENIGMA-TRS Phase III trials position Newron to address a large unmet need in schizophrenia, potentially strengthening its standing in neuropsychiatry and offering new options for patients who lack effective treatments today.

The most recent analyst rating on (CH:NWRN) stock is a Hold with a CHF21.50 price target. To see the full list of analyst forecasts on Newron Pharmaceuticals SpA stock, see the CH:NWRN Stock Forecast page.

More about Newron Pharmaceuticals SpA

Newron Pharmaceuticals is an Italy-based biopharmaceutical company specializing in therapies for central and peripheral nervous system diseases, with a track record from discovery to market launch. Its lead candidate, Evenamide, is a first-in-class glutamate modulator in Phase III development for treatment-resistant schizophrenia, while its marketed drug Xadago treats Parkinson’s disease globally via multiple commercial partners.

Average Trading Volume: 146,155

Technical Sentiment Signal: Buy

Current Market Cap: CHF312.2M

See more insights into NWRN stock on TipRanks’ Stock Analysis page.